Medigen Vaccine Biologics (ROCO:6547) Altman Z2-Score: 10.97 (As of Jul. 07, 2026) — 135% Above Median


ROCO:6547 Medigen Vaccine Biologics Corp ROCO:6547
67 GF Score
Price NT$48.00
GF Value NT$70.21
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Medigen Vaccine Biologics Altman Z2-Score?

Medigen Vaccine Biologics ROCO:6547 +3.56% 67 Altman Z2-Score is 10.97 as of Jul. 07, 2026, which is 135% above its 10-year median of 4.66. GuruFocus rates ROCO:6547 with a GF Score™ of 67/100 and a GF Value™ of NT$70.21 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,390 Biotechnology companies, Medigen Vaccine Biologics ranks better than 83.74% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Medigen Vaccine Biologics has a Altman Z2-Score of 10.97, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Medigen Vaccine Biologics's Altman Z2-Score or its related term are showing as below:

ROCO:6547' s Altman Z2-Score Range Over the Past 10 Years
Min: -0.24   Med: 4.66   Max: 14.61
Current: 10.97

During the past 13 years, Medigen Vaccine Biologics's highest Altman Z2-Score was 14.61. The lowest was -0.24. And the median was 4.66.


Medigen Vaccine Biologics  (ROCO:6547) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Medigen Vaccine Biologics Altman Z2-Score Related Terms


Medigen Vaccine Biologics Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Medigen Vaccine Biologics's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Vaccine Biologics Altman Z2-Score Chart

Medigen Vaccine Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.61 4.95 2.53 11.23 10.97

Medigen Vaccine Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.23 11.46 11.47 11.52 10.97

ROCO:6547 vs VRTX, REGN, ALNY: Altman Z2-Score Comparison

For the Biotechnology subindustry, Medigen Vaccine Biologics's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Vaccine Biologics Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Medigen Vaccine Biologics's Altman Z2-Score falls into.


ROCO:6547
67GF Score
Medigen Vaccine Biologics Corp ROCO:6547
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Vaccine Biologics Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Medigen Vaccine Biologics's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.5536+3.26*-0.0716+6.72*-0.0694+1.05*7.6527
=10.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was NT$3,933.9 Mil.
Total Current Assets was NT$2,362.8 Mil.
Total Current Liabilities was NT$185.0 Mil.
Retained Earnings was NT$-281.7 Mil.
Pre-Tax Income was -138.184 + -22.598 + -99.887 + -21.045 = NT$-281.7 Mil.
Interest Expense was -2.145 + -2.17 + -2.215 + -2.272 = NT$-8.8 Mil.
Total Liabilities was NT$454.6 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(2362.757 - 185.045)/3933.908
=0.5536

X2=Retained Earnings/Total Assets
=-281.714/3933.908
=-0.0716

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-281.714 - -8.802)/3933.908
=-0.0694

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(3479.264 - 0)/454.644
=7.6527

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Medigen Vaccine Biologics has a Altman Z2-Score of 10.97 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 10.97 mean?
Medigen Vaccine Biologics (ROCO:6547) has a Altman Z2-Score of 10.97 as of Jul. 07, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Medigen Vaccine Biologics and its competitors. This is 135% above median its historical median of 4.66. According to the industry distribution chart, Medigen Vaccine Biologics ranks #226 out of 1390 companies in the Biotechnology industry, placing it in the top 16.3%.
Is Medigen Vaccine Biologics' Altman Z2-Score too high?
Medigen Vaccine Biologics' current Altman Z2-Score of 10.97 is 135% above median its 10-year median of 4.66. Based on the distribution chart, Medigen Vaccine Biologics ranks #226 out of 1390 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medigen Vaccine Biologics has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #226 out of 1390 companies for Altman Z2-Score. This places Medigen Vaccine Biologics in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Medigen Vaccine Biologics and its competitors. Medigen Vaccine Biologics's current Altman Z2-Score is 10.97, which is 135% above median its own 10-year median of 4.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.21, compared to a current price of NT$48.00 — trading 31.6% below its estimated fair value. The current Altman Z2-Score is 10.97, which is 135% above median its 10-year median of 4.66. Medigen Vaccine Biologics' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Altman Z2-Score is 10.97 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued. The current stock price of NT$48.00 is trading 31.6% below its estimated GF Value™ of NT$70.21. GuruFocus considers Medigen Vaccine Biologics to be Possible Value Trap.

Key valuation signals for ROCO:6547:

  • Altman Z2-Score: 10.97 (135% above median its 10-year median of 4.66)
  • GF Value™: NT$70.21 vs. price of NT$48.00 (31.6% below fair value)
  • GF Score™: 67/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medigen Vaccine Biologics Business Description

Address 302 No. 68, Shengyi 3rd Road, Hsinchu County, Zhubei, TWN, 30261
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
67GF Score

Get the complete analysis for ROCO:6547

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$48.00
Price
NT$70.21
GF Value